Last update 14 Nov 2024
AD-010
Last update 14 Nov 2024
Overview
Basic Info
Drug Type Protein drugs |
Synonyms blood clotting regulatory protein(Jiangsu Aidea Pharmaceutical), coagulation regulatory protein(Jiangsu Aidea Pharmaceutical), natural thrombomodulin(Jiangsu Aidea Pharmaceutical) + [4] |
Target |
Mechanism THBD stimulants(Thrombomodulin stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Related
1
Clinical Trials associated with AD-010The retrospective study of treatment by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis, acute respiratory distress sydmrome - The treatment of thrombomodulin for acute respiratory failure
100 Clinical Results associated with AD-010
Login to view more data
100 Translational Medicine associated with AD-010
Login to view more data
100 Patents (Medical) associated with AD-010
Login to view more data
277
Literatures (Medical) associated with AD-01016 Sep 2024Future Medicinal Chemistry
Molecular docking, derivatization, characterization and biological assays of amantadine
Article
Author: Awan, Breena ; Ullah, Farhat ; Ahmad, Irshad ; Khan, Muhammad Rizwan ; Khan, Mohsin Abbas ; Akram, Muhammad Toseef ; Yasmeen, Zarmeena
Background: Derivatization has been tremendously utilized in the field of drug discovery for optimizing the pharmacological properties and improving safety, efficacy and selectivity.Methodology: Schiff's bases (AD1-AD11) are synthesized through amantadine condensation with different aldehydes and ketones. Fourier transform infrared, 1H NMR, 13C NMR, TLC, liquid chromatography mass spectrometry analysis, in silico studies, molecular docking and antiviral activity through hemagglutinin test were performed for evaluation of new compounds.Results: AD2, 3 and 9-11 showed greater antiviral activity than the parent drug. Among all derivatives, AD2 and AD3 exhibited good potential against α-amylase while AD7 and AD10 showed stronger inhibition against α-glucosidase.Conclusion: So, it is concluded that the most potent derivatives can be used as lead compounds in novel drug design of antiviral antidiabetic agents.
28 Aug 2024Cureus Journal of Medical Science
Iliopsoas Abscess, Spondylodiscitis, Septic Pulmonary Embolism, and Symmetrical Peripheral Gangrene by Hypermucoviscous Klebsiella pneumoniae
Article
Author: Hayashi, Maho ; Hayashi, Koji ; Shirasaki, Akihisa ; Yamamoto, Chie ; Morikawa, Yukie ; Hamada, Hina
Hypermucoviscous Klebsiella pneumoniae (hmKP) is a bacterium known to cause lesions, including abscesses, in various organs. Unlike typical Klebsiella pneumoniae, hmKP can yield a positive string test in culture specimens. Infections caused by hmKP often become severe and are associated with a poor prognosis. In this report, we describe a case of iliopsoas abscess, spondylodiscitis, septic pulmonary embolism, and symmetrical peripheral gangrene (SPG) caused by hmKP. The patient received non-invasive positive-pressure ventilation, hemodialysis, platelet transfusions, fresh frozen plasma, thrombomodulin, and intensive antibiotic therapy including rifampicin. The patient underwent 148 days of antibiotic therapy and achieved a good outcome.
01 Jul 2024INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Thrombomodulin Improves Cognitive Deficits in Heat-Stressed Mice
Article
Author: Chang, Ching-Ping ; Tang, Ling-Yu ; Lin, Cheng-Hsien ; Wang, Lin-Yu
Abstract:
Background:
Thrombomodulin (TM) exerts anticoagulant and anti-inflammatory effects to improve the survival of patients with septic shock. Heat stroke resembles septic shock in many aspects. We tested whether TM would improve cognitive deficits and related causative factors in heat-stressed (HS) mice.
Methods:
Adult male mice were exposed to HS (33°C for 2 hours daily for 7 consecutive days) to induce cognitive deficits. Recombinant human soluble TM (1 mg/kg, i.p.) was administered immediately after the first HS trial and then once daily for 7 consecutive days. We performed the Y-maze, novel objective recognition, and passive avoidance tests to evaluate cognitive function. Plasma levels of lipopolysaccharide (LPS), high-mobility group box 1 (HMGB1), coagulation parameters, and both plasma and tissue levels of inflammatory and oxidative stress markers were biochemically measured. The duodenum and hippocampus sections were immunohistochemically stained. The intestinal and blood-brain barrier permeability were determined.
Results:
Compared with controls, HS mice treated with TM had lesser extents of cognitive deficits, exacerbated stress reactions, gut barrier disruption, endotoxemia, blood-brain barrier disruption, and inflammatory, oxidative, and coagulatory injury to heart, duodenum, and hippocampal tissues, and increased plasma HMGB1. In addition to reducing cognitive deficits, TM therapy alleviated all the abovementioned complications in heat-stressed mice.
Conclusions:
The findings suggest that HS can lead to exacerbated stress reactions, endotoxemia, gut barrier disruption, blood-brain barrier disruption, hippocampal inflammation, coagulopathy, and oxidative stress, which may act as causative factors for cognitive deficits. TM, an anti-inflammatory, antioxidant, and anti-coagulatory agent, inhibited heat stress-induced cognitive deficits in mice.
100 Deals associated with AD-010
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Disseminated Intravascular Coagulation | Preclinical | CN | - | |
| Inflammation | Preclinical | CN | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free